Debio 2512
The Debio 2512 program is leveraging a bispecific HER3-HER2 targeted antibody, licensed from SunRock Biopharma, with our proprietary Multilink™ Linker Technology, to create an innovative antibody drug conjugate (ADC). This novel ADC will target tumor-specific antigens to fight cancer with high unmet medical needs.
Debiopharm’s ADC expertise
We’re developing fit-for-purpose antibody drug conjugates through a tailored “Trifecta” approach: strategic target selection, innovative Multilink™ linker technology and smart payload choices. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and multiple payloads, leveraging our solid development experience to accelerate ADC products to patients.
